AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
Primary and secondary endpoint reporting remains pending after completion of Ampligen dosing in the DURIPANC combination trial.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech (AIM) highlighted a BioTuesdays feature examining Ampligen’s potential as maintenance therapy after first-line chemotherapy for metastatic pancreatic cancer.
Final Ampligen dosing is complete in DURIPANC, which evaluates Ampligen with AstraZeneca’s Imfinzi; primary and secondary endpoint reporting remains pending. AIM is working toward further clinical development. In an exploratory Named Patient Program analysis, 39 patients with a neutrophil-to-lymphocyte ratio, an immune-cell measure, below 4.5 had median overall survival of 34.8 months from the start of FOLFIRINOX chemotherapy. The program was not a controlled clinical trial, and historical comparisons do not establish efficacy. The feature also discusses patents, pancreatic cancer orphan drug designations and potential financing or pharmaceutical partnerships to support a pivotal Phase 3 study.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFinal Ampligen dosing completed in DURIPANC, evaluating the combination with Imfinzi after first-line chemotherapy.
- Minor pointExploratory median overall survival: 34.8 months from FOLFIRINOX initiation in 39 patients with neutrophil-to-lymphocyte ratios below 4.5.
- Minor point. Forward-looking: it has not happened yet and may not happen.AIM is working toward further clinical development as it awaits DURIPANC endpoint reporting.
- Minor pointPatents cover Ampligen combined with checkpoint inhibitors, drugs that help immune cells attack cancer.
- Minor pointPancreatic cancer orphan drug designations cover Ampligen in the United States and European Union.
Negative
- Moderate pointDURIPANC primary and secondary endpoints remain awaiting reporting.
- Minor pointNamed Patient Program was not controlled; comparisons with historical controls do not establish treatment efficacy.
Key Figures
- Subgroup size
- 39 patients
- Exploratory Named Patient Program analysis
- NLR cutoff
- below 4.5
- Criterion for the exploratory patient subgroup
- Median overall survival
- 34.8 months
- Measured from FOLFIRINOX start; exploratory analysis, not a controlled trial
Historical Context
-
CEO video reported the same exploratory subgroup median survival of 34.8 months from FOLFIRINOX start.
-
DURIPANC completed final dosing; AIM said topline results were expected in the first quarter of 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nlr medical
folfirinox medical
checkpoint inhibitors medical
orphan drug designations regulatory
median overall survival medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development
Access the article here
OCALA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today spotlighted a BioTuesdays feature examining the Company’s strategy to address the critical treatment gap of maintaining disease control after first-line chemotherapy for metastatic pancreatic cancer. The article features an interview with AIM Chief Executive Officer Thomas K. Equels and explores the scientific and clinical foundation supporting Ampligen®’s (rintatolimod) potential as a pancreatic cancer maintenance therapy.
Read the full BioTuesdays article, "AIM advancing immunology solutions for globally important diseases"
The feature examines Ampligen’s potential to convert the immunosuppressive tumor microenvironment, turning “cold” tumors into a more immunologically active state and thus enabling checkpoint inhibitors to work more effectively. This approach is being evaluated in a clinical trial of Ampligen in combination with AstraZeneca’s Imfinzi® (durvalumab) following first-line chemotherapy (the “DURIPANC” trial). With final Ampligen dosing complete, AIM is working toward the next stage of clinical development as it awaits the reporting of primary and secondary endpoints.
“For patients with metastatic pancreatic cancer, extending survival and improving quality of life are the outcomes that matter most,” said AIM Chief Executive Officer Thomas K. Equels. “The BioTuesdays feature captures why we are pursuing Ampligen in this setting: the urgent need for an effective maintenance therapy and the potential to address the immune resistance that makes pancreatic cancer so difficult to treat. With Ampligen dosing complete, our focus is on translating the anticipated clinical findings and biomarker research into a path toward pivotal development. Our mission is to give patients more time, better quality of life and hope.”
BioTuesdays also examines encouraging survival and quality-of-life observations from AIM’s Netherlands-approved Named Patient Program, which provided Ampligen to patients with pancreatic cancer following FOLFIRINOX. Exploratory analyses identified patient subgroups with favorable survival observations based on immune and tumor biomarkers. The segment also highlights observations from a Dutch Named Patient Program (NPP) in which patients with radiologically stable pancreatic cancer after FOLFIRINOX received Ampligen as a maintenance treatment. In an exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio (“NLR”) below 4.5, median overall survival was 34.8 months, measured from the start of FOLFIRINOX. This encouraging observation supports further investigation of Ampligen following chemotherapy. These findings are informing AIM’s efforts to better understand patient response and guide future trial design. The Named Patient Program was not a controlled clinical trial, and comparisons with historical controls do not establish treatment efficacy.
The article brings together the clinical observations, mechanism of action and biomarker research underpinning AIM’s pancreatic cancer strategy. It also discusses the Company’s patents covering Ampligen in combination with checkpoint inhibitors, pancreatic cancer orphan drug designations in the United States and European Union, and potential financing or pharmaceutical partnership pathways to support a pivotal Phase 3 study.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating, but not limited to: the potential of Ampligen to address immune resistance in pancreatic cancer through its immune-modulating activity; the potential of Ampligen in combination with AstraZeneca’s Imfinzi (durvalumab) in the Phase 2 DURIPANC clinical trial; and the timing and outcome of the DURIPANC topline results; the Company’s long-term pancreatic cancer development strategy and its efforts to position Ampligen for the next stage of development; and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.
For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What survival observation did AIM report for Ampligen in pancreatic cancer?
An exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio below 4.5 found median overall survival of 34.8 months, measured from the start of FOLFIRINOX. Patients received Ampligen as maintenance treatment after radiologically stable disease following FOLFIRINOX. The Named Patient Program was not a controlled clinical trial, and historical comparisons do not establish efficacy.
What is the status of AIM’s DURIPANC trial of Ampligen with Imfinzi?
Final Ampligen dosing is complete, while reporting of primary and secondary endpoints remains pending. DURIPANC evaluates Ampligen combined with AstraZeneca’s Imfinzi after first-line chemotherapy. AIM is working toward the next stage of clinical development.